View in EDS

Orforglipron for maintenance of body weight reduction: the double-blind, randomized phase 3b ATTAIN-MAINTAIN trial.

Saved in:
Bibliographic Details
Title: Orforglipron for maintenance of body weight reduction: the double-blind, randomized phase 3b ATTAIN-MAINTAIN trial.
Authors: Aronne LJ; Comprehensive Weight Control Center, Division of Endocrinology, Diabetes and Metabolism, Weill Cornell Medicine, New York, NY, USA. ljaronne@med.cornell.edu., Horn DB; Center for Obesity Medicine and Metabolic Performance, Departments of Surgery and Internal Medicine, University of Texas McGovern Medical School, Houston, TX, USA., le Roux CW; Metabolic Medicine, School of Medicine, Conway Institute, University College Dublin, Dublin, Ireland.; Diabetes Research Centre, Ulster University, Coleraine, UK., Chao AM; Johns Hopkins School of Nursing, Baltimore, MD, USA., Ho W; Keck School of Medicine of University of Southern California, Los Angeles, CA, USA., Halpern B; Obesity Center, Nove de Julho Hospital, São Paulo, Brazil., Griffin R; Eli Lilly and Company, Indianapolis, IN, USA., Xie C; Eli Lilly and Company, Indianapolis, IN, USA., Valderas EG; Eli Lilly and Company, Indianapolis, IN, USA., Lee CJ; Eli Lilly and Company, Indianapolis, IN, USA., Ribeiro A; Eli Lilly and Company, Indianapolis, IN, USA., Hyman DM; Eli Lilly and Company, Indianapolis, IN, USA., Glass L; Eli Lilly and Company, Indianapolis, IN, USA., Xavier N; Eli Lilly and Company, Indianapolis, IN, USA.
Source: Nature medicine [Nat Med] 2026 May 13. Date of Electronic Publication: 2026 May 13.
Publication Type: Journal Article
Journal Info: Publisher: Nature Publishing Company Country of Publication: United States NLM ID: 9502015 Publication Model: Print-Electronic Cited Medium: Internet ISSN: 1546-170X (Electronic) Linking ISSN: 10788956 NLM ISO Abbreviation: Nat Med Subsets: MEDLINE
Database: MEDLINE Ultimate
FullText Text:
  Availability: 0
Header DbId: mdl
DbLabel: MEDLINE Ultimate
An: 42120723
AccessLevel: 2
PubType: Academic Journal
PubTypeId: academicJournal
PreciseRelevancyScore: 0
IllustrationInfo
Items – Name: Title
  Label: Title
  Group: Ti
  Data: Orforglipron for maintenance of body weight reduction: the double-blind, randomized phase 3b ATTAIN-MAINTAIN trial.
– Name: Author
  Label: Authors
  Group: Au
  Data: <searchLink fieldCode="AU" term="%22Aronne+LJ%22">Aronne LJ</searchLink>; Comprehensive Weight Control Center, Division of Endocrinology, Diabetes and Metabolism, Weill Cornell Medicine, New York, NY, USA. ljaronne@med.cornell.edu.<br /><searchLink fieldCode="AU" term="%22Horn+DB%22">Horn DB</searchLink>; Center for Obesity Medicine and Metabolic Performance, Departments of Surgery and Internal Medicine, University of Texas McGovern Medical School, Houston, TX, USA.<br /><searchLink fieldCode="AU" term="%22le+Roux+CW%22">le Roux CW</searchLink>; Metabolic Medicine, School of Medicine, Conway Institute, University College Dublin, Dublin, Ireland.; Diabetes Research Centre, Ulster University, Coleraine, UK.<br /><searchLink fieldCode="AU" term="%22Chao+AM%22">Chao AM</searchLink>; Johns Hopkins School of Nursing, Baltimore, MD, USA.<br /><searchLink fieldCode="AU" term="%22Ho+W%22">Ho W</searchLink>; Keck School of Medicine of University of Southern California, Los Angeles, CA, USA.<br /><searchLink fieldCode="AU" term="%22Halpern+B%22">Halpern B</searchLink>; Obesity Center, Nove de Julho Hospital, São Paulo, Brazil.<br /><searchLink fieldCode="AU" term="%22Griffin+R%22">Griffin R</searchLink>; Eli Lilly and Company, Indianapolis, IN, USA.<br /><searchLink fieldCode="AU" term="%22Xie+C%22">Xie C</searchLink>; Eli Lilly and Company, Indianapolis, IN, USA.<br /><searchLink fieldCode="AU" term="%22Valderas+EG%22">Valderas EG</searchLink>; Eli Lilly and Company, Indianapolis, IN, USA.<br /><searchLink fieldCode="AU" term="%22Lee+CJ%22">Lee CJ</searchLink>; Eli Lilly and Company, Indianapolis, IN, USA.<br /><searchLink fieldCode="AU" term="%22Ribeiro+A%22">Ribeiro A</searchLink>; Eli Lilly and Company, Indianapolis, IN, USA.<br /><searchLink fieldCode="AU" term="%22Hyman+DM%22">Hyman DM</searchLink>; Eli Lilly and Company, Indianapolis, IN, USA.<br /><searchLink fieldCode="AU" term="%22Glass+L%22">Glass L</searchLink>; Eli Lilly and Company, Indianapolis, IN, USA.<br /><searchLink fieldCode="AU" term="%22Xavier+N%22">Xavier N</searchLink>; Eli Lilly and Company, Indianapolis, IN, USA.
– Name: TitleSource
  Label: Source
  Group: Src
  Data: <searchLink fieldCode="JN" term="%229502015%22">Nature medicine</searchLink> [Nat Med] 2026 May 13. <i>Date of Electronic Publication: </i>2026 May 13.
– Name: TypePub
  Label: Publication Type
  Group: TypPub
  Data: Journal Article
– Name: TitleSource
  Label: Journal Info
  Group: Src
  Data: <i>Publisher: </i><searchLink fieldCode="PB" term="%22Nature+Publishing+Company%22">Nature Publishing Company </searchLink><i>Country of Publication: </i>United States <i>NLM ID: </i>9502015 <i>Publication Model: </i>Print-Electronic <i>Cited Medium: </i>Internet <i>ISSN: </i>1546-170X (Electronic) <i>Linking ISSN: </i><searchLink fieldCode="IS" term="%2210788956%22">10788956 </searchLink><i>NLM ISO Abbreviation: </i>Nat Med <i>Subsets: </i>MEDLINE
PLink https://search.ebscohost.com/login.aspx?direct=true&site=eds-live&db=mdl&AN=42120723
RecordInfo BibRecord:
  BibEntity:
    Identifiers:
      – Type: doi
        Value: 10.1038/s41591-026-04386-7
    Languages:
      – Code: eng
        Text: English
    Titles:
      – TitleFull: Orforglipron for maintenance of body weight reduction: the double-blind, randomized phase 3b ATTAIN-MAINTAIN trial.
        Type: main
  BibRelationships:
    HasContributorRelationships:
      – PersonEntity:
          Name:
            NameFull: Aronne LJ
      – PersonEntity:
          Name:
            NameFull: Horn DB
      – PersonEntity:
          Name:
            NameFull: le Roux CW
      – PersonEntity:
          Name:
            NameFull: Chao AM
      – PersonEntity:
          Name:
            NameFull: Ho W
      – PersonEntity:
          Name:
            NameFull: Halpern B
      – PersonEntity:
          Name:
            NameFull: Griffin R
      – PersonEntity:
          Name:
            NameFull: Xie C
      – PersonEntity:
          Name:
            NameFull: Valderas EG
      – PersonEntity:
          Name:
            NameFull: Lee CJ
      – PersonEntity:
          Name:
            NameFull: Ribeiro A
      – PersonEntity:
          Name:
            NameFull: Hyman DM
      – PersonEntity:
          Name:
            NameFull: Glass L
      – PersonEntity:
          Name:
            NameFull: Xavier N
    IsPartOfRelationships:
      – BibEntity:
          Dates:
            – D: 13
              M: 05
              Text: 2026 May 13
              Type: published
              Y: 2026
          Identifiers:
            – Type: issn-electronic
              Value: 1546-170X
          Titles:
            – TitleFull: Nature medicine
              Type: main
ResultId 1